Similar articles

• Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease.

  Colao A, Pivonello R, Lastoria S, Faggiano A, Ferone D, Lombardi G, Fenzi G. Colao A, et al. Eur J Endocrinol. 2000 Oct;143 Suppl 1:S35-42. doi: 10.1530/eje.0.143s035. Eur J Endocrinol. 2000. PMID: 11068938 Review. No abstract available.
• [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?

  Postema PT, Krenning EP, Wijngaarde R, Kooy PP, Oei HY, van den Bosch WA, Reubi JC, Wiersinga WM, Hooijkaas H, van der Loos T, et al. Postema PT, et al. J Clin Endocrinol Metab. 1994 Dec;79(6):1845-51. doi: 10.1210/jcem.79.6.7989493. J Clin Endocrinol Metab. 1994. PMID: 7989493
• What is a false-positive somatostatin receptor scintigraphy?

  Reubi JC. Reubi JC. J Nucl Med. 1998 Dec;39(12):2193-4. J Nucl Med. 1998. PMID: 9867170 No abstract available.
• 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.

  Bohuslavizki KH, Oberwöhrmann S, Brenner W, Eberhardt JU, Mönig H, Clausen M, Sippel C, Wolf H, Epe B, Henze E. Bohuslavizki KH, et al. Nucl Med Commun. 1995 Nov;16(11):912-6. doi: 10.1097/00006231-199511000-00006. Nucl Med Commun. 1995. PMID: 8587756
• Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.

  Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW. Krenning EP, et al. Ann N Y Acad Sci. 1994 Sep 15;733:416-24. doi: 10.1111/j.1749-6632.1994.tb17291.x. Ann N Y Acad Sci. 1994. PMID: 7978890 Review. No abstract available.